So dear readers, do check out this preview of Teenage Mutant Ninja Turtles #9 when it hits stores Wednesday, and consider purchasing a copy – it may very well be the last comic you enjoy as free ...

Pyrene and its derivatives are widely utilized for their fluorescent behavior, and excimer formation allows the study of molecular structural behavior. Hence, it was hypothesized that ...

Background: BREAKWATER (NCT04607421) is an open-label, global, randomized, phase 3 study evaluating first-line (1L) encorafenib + cetuximab (EC) ± chemotherapy (chemo) vs standard of care (SOC; chemo ...

The new drug application (NDA) seeking full approval of ziftomenib (KO-539) in relapsed/refractory acute myeloid leukemia (AML) harboring an NPM1 mutation has received FDA priority review.; A target ...

Summary:. Mutations in the TP53 tumor-suppressor gene in human cancer are unique in that 60% to 70% are of the missense variety, resulting in a full-length protein that is often highly expressed in ...

Marvel has unveiled a new mutant with a very old connection to Jean Grey, and her power might just change everything. Marvel Revealed a Surprising Character’s Mutant Power and it Could Have ...

The Teenage Mutant Ninja Turtles and Team Seven have defeated the Foot Clan’s mutated forces, but the battle is far from over: Using the power of the ooze, Oroku Saki has abandoned his humanity ...

Despite the development of anti-cancer drugs targeting KRAS(G12) mutants, drugs targeting NRAS(Q61) mutants — key oncogenic drivers of melanoma — remain lacking. Hauseman, Stauffer, Beyer and ...

Regulatory submission is based on positive results from the ongoing Phase I/II SOHO-01 trial in patients with advanced HER2-mutant non-small cell lung cancer (NSCLC). Investigational agent ...

With the exponential growth of AI computing power, the power density of electronic devices has exceeded 1 kW/cm2, rendering traditional thermal management materials insufficient to handle the ...

Background: The DREAMseq trial compared efficacy and toxicity of the sequence of nivolumab/ipilimumab (N/I) followed by dabrafenib/trametinib (D/T) to the reverse sequence in patients (pts) with ...